Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C65H92N14O18S2 |
| Molecular Weight | 1421.6437 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN3CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC3)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)N[C@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
InChI
InChIKey=RZHKDBRREKOZEW-AAXZNHDCSA-N
InChI=1S/C65H92N14O18S2/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90)/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+/m1/s1
| Molecular Formula | C65H92N14O18S2 |
| Molecular Weight | 1421.6437 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Edotreotide (SMT487) is a DOTA-containing somatostatin analog. Edotreotide binds with high affinity to somatostatin receptors. Somatostatin receptors are predominantly overexpressed by neuroendocrine tumors. On 15 September 2016, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorisation for the orphan medicine edotreotide (SomaKit-TOC) intended for use in Positron Emission Tomography (PET) imaging in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs). SomaKit TOC was designated as an orphan medicinal product on 19 March 2015. 68Ga-Edotreotide, distributed under the brand name TOCscan® (Sogacin® in Austria/ France), is the companion diagnostic in ITM´s theranostic approach for the treatment of neuroendocrine tumors (NETs). N.c.a. 177Lu-Edotreotide is known as an innovative Targeted Radionuclide Therapy agent with favorable safety profile and promising efficacy. N.c.a. 177Lu-Edotreotide received an Orphan Designation as treatment of gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) based on academic clinical Phase II data suggesting a significant benefit (substantially improved progression-free survival, PFS).
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:28:04 GMT 2025
by
admin
on
Mon Mar 31 18:28:04 GMT 2025
|
| Record UNII |
U194AS08HZ
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C62799
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
||
|
FDA ORPHAN DRUG |
160902
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
204318-14-9
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
CHEMBL408350
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
SUB179386
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
100000164814
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
8032
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
158782
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
m4831
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | Merck Index | ||
|
C106246
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
U194AS08HZ
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
DTXSID701021591
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
OO-07
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
C2616
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY | |||
|
EDOTREOTIDE
Created by
admin on Mon Mar 31 18:28:04 GMT 2025 , Edited by admin on Mon Mar 31 18:28:04 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
LABELED -> NON-LABELED |
|
||
|
PARENT -> DERIVATIVE |
|
||
|
|
LABELED -> NON-LABELED |
|
||
|
TARGET->LIGAND |
|
||
|
|
LABELED -> NON-LABELED |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
LABELED -> NON-LABELED |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|